Browse diseases

…Background and Importance Treatment burden in neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME) is an issue for patien…

…aintaining functional and anatomical outcomes for patients with neovascular age-related macular degeneration.Methods We integrated population pharmacokinetic/pharmacodynami…

…imilars compared with reference aflibercept in the treatment of neovascular age-related macular degeneration (nAMD).Methods A systematic review and meta-analysis were condu…

… diagnosis of retinal vasculitis, ocular ischaemic syndrome and proliferative diabetic retinopathy, even when OCTA is available. Furthermore, FFA was the favoured…

…and structural optical coherence tomography (OCT)—for detecting macular atrophy (MA) in patients with previously treated neovascular age-relate…

…on.Methods Retrospective, observational study. Stable, inactive nAMD patients who had been treated with a treat-and-extend regimen a…

…uating ranibizumab, brolucizumab, aflibercept, and faricimab in nAMD. Baseline characteristics included age, sex, race, best-correct…

…Background and Importance Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss in older …

…ment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME). Unlike previous anti-VEGF agents, faricimab targets both…

…iaodong S, Berliner AJ, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non…

…egol (ACP), a Food and Drug Administration-approved therapy for geographic atrophy, administered in combination with ranibizumab, an approved ther…

… aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration (nAMD).Methods and analysis Patients aged ≥50 years with newly …